Ascent Wealth Partners’s Whitehawk Therapeutics WHWK Stock Holding History

Ascent Wealth Partners’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,000	Closed	-$241K	–	160
2021 Q4	$241K	Buy	+10,000	New	+$251K	0.04%	138
2021 Q3	–	Sell	-667	Closed	-$17K	–	152
2021 Q2	$17K	Hold	667	–	–	﹤0.01%	148
2021 Q1	$13K	Hold	667	–	–	﹤0.01%	121
2020 Q4	$10K	Hold	667	–	–	﹤0.01%	116
2020 Q3	$15K	Hold	667	–	–	﹤0.01%	111
2020 Q2	$12K	Hold	667	–	–	﹤0.01%	107
2020 Q1	$5K	Hold	667	–	–	﹤0.01%	107
2019 Q4	$6K	Hold	667	–	–	﹤0.01%	118
2019 Q3	$7K	Hold	667	–	–	﹤0.01%	117
2019 Q2	$9K	Hold	667	–	–	﹤0.01%	118
2019 Q1	$9K	Hold	667	–	–	﹤0.01%	133
2018 Q4	$17K	Hold	667	–	–	0.01%	118
2018 Q3	$31K	Hold	667	–	–	0.01%	124
2018 Q2	$41K	Buy	+667	New	+$40.3K	0.01%	122

Other funds holding WHWK

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ascent Wealth Partners's WHWK Position: Q1 2022 in Review

Ascent Wealth Partners sold out of Whitehawk Therapeutics (WHWK) in Q1 2022, closing a stake of 10,000 shares — an estimated $241K sold.

Ascent Wealth Partners first reported a position in WHWK in Q2 2018 and held it in 14 quarters. The position peaked at $241K in Q4 2021. 55 funds tracked by Wall St. Rank hold WHWK as of Q1 2022.

Ascent Wealth Partners reported no remaining Whitehawk Therapeutics position as of Q1 2022 after selling out during the quarter.
Ascent Wealth Partners sold 10,000 Whitehawk Therapeutics shares in Q1 2022, an estimated $241K.
Ascent Wealth Partners first reported a position in Whitehawk Therapeutics in Q2 2018 and held it in 14 quarters.
Ascent Wealth Partners's Whitehawk Therapeutics position peaked at $241K in Q4 2021.
55 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2022.

Based on Ascent Wealth Partners's 13F filing for Q1 2022, filed 2 May 2022.